Lisbon, Portugal – Dr Gerard O’Sullivan announced preliminary results from a European study of venous stents today at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015, a European meeting for interventional radiologists and vascular specialists. Dr O’Sullivan is the principal investigator of the VIVO-EU study at the University Hospital Galway.
Titled “An Update on VIVO-EU, a Prospective Study of the Zilver Vena Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction,” Dr O’Sullivan’s talk focused on the interim study results. The study has reached full enrolment and three-quarters of patients have been followed for six months or longer.
Thirty-five (35) patients with symptomatic iliofemoral outflow obstruction were enrolled into the study. These patients had leg pain that limited their usual activity, swelling or skin discoloration in their leg. Study physicians reported that all stents deployed as intended and no stent was scored as difficult to deploy. At procedure, Zilver Vena stent placement resulted in a more than two-fold improvement in the vessel minimum lumen diameter. Based on available follow-up data, stent placement has corresponded to improved clinical symptoms.
“This is the first venous stent trial using a stent designed for the rigours of venous disease,” said Mark Breedlove, vice president of Cook Medical’s Peripheral Intervention division “It shows why venous stenting is an important part of treating venous disease.”
Evaluation of the Zilver Vena Venous Stent (VIVO EU) is a prospective, non-randomized, multi-centre study intended to evaluate the Zilver Vena stent in the treatment of symptomatic iliofemoral venous outflow obstruction. Patients involved in the study will be followed after their procedure to monitor complication rates and improvement of symptoms.
Dr O’Sullivan, a principal investigator for the VIVO EU trial, is a paid consultant of Cook Medical.
About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at cookmedical.eu, and for the latest news, follow us on Twitter, Facebook and LinkedIn.